News | October 28, 2013

CBSET Presents Preclinical Development Data on Renal Denervation Devices

October 28, 2013 — CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education and advancement of medical technologies, will present data from the podium at the Transcatheter Cardiovascular Therapeutics annual scientific meeting (TCT 2013) that provides a seminal experimental and computational template for a more rational, comprehensive preclinical evaluation and optimization of renal denervation devices.
 
Elazer Edelman, M.D., Ph.D., chairman and co-founder, CBSET, will present the data “Electrode irrigation alters RF ablation treatment zone geometry and protects intimal and medial tissue while maintaining injury to renal nerves.”
 
“Although the anti-hypertensive drug market is $18 billion annually, about half of hypertensive patients who are on drug therapy do not achieve adequate control of their blood pressure,” said Peter Markham, president, CEO and co-founder, CBSET. “Therefore the door is wide open for effective hypertension therapies in this population, such as renal denervation devices…. By coupling quantification of the efficacy biomarker of renal denervation — NEPI, or norepinephrine — with the histopathological evaluation and computational prediction of the ablation lesion, we now have the template for a more rational and comprehensive preclinical evaluation and optimization of renal denervation devices. Given that 20 percent of patients are non-responders to renal denervation devices, we believe that this patient population will ultimately benefit from this next level of understanding of a complex process that has been demystified by our scientists.”
 
“The CBSET data provide a unique perspective on the determinants of the efficacy of renal denervation devices,” said Edelman. “The computational models developed by Dr. Rami Tzafriri, principal scientist at CBSET, help explain how to understand the impact of renal denervation and how to optimize this emerging technology. These studies in particular shed light on the importance of treatment parameters such as electrode power and duration while also revealing the dependence of RF (radiofrequency) energy delivery on the structure of perivascular tissues that vary between individuals,” added Dr. Edelman. “CBSET has raised the bar in empowering the medical device industry to understand how best to manage renal denervation to reduce blood pressure in a larger patient population.”
 
For more information: www.cbset.org
 

Related Content

The Medtronic Symplicity Spyral renal denervation catheter in the renal artery, showing how its four electrodes contact the vessel wall for a single RF energy delivery procedure. By ablating the vessel walls, it props the vessel in a fully open position, allowing the kidneys to better filter the blood and remove excess water in hypertension patients. RDN

The Medtronic Symplicity Spyral renal denervation catheter in the renal artery, showing how its four electrodes contact the vessel wall for a single RF energy delivery procedure. By ablating the vessel walls, it props the vessel in a fully open position, allowing the kidneys to better filter the blood and remove excess water in hypertension patients.

News | Renal Denervation | June 26, 2020
June 26, 2020 – New data from the Global SY...
News | Renal Denervation | April 01, 2020
April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure ha
News | Renal Denervation | April 01, 2020
April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure ha
Medtronic Presents Positive Renal Denervation Results at EuroPCR 2019
News | Renal Denervation | May 23, 2019
Investigators unveiled late-breaking clinical data from a first-of-its-kind physician sponsored clinical trial at the...
An example of renal denervation therapy being delivered. A catheter is inserted into the renal artery to ablate the nerves in the vessel wall that regulate vasoconstriction. This leaves the vessel permanently in the widest open position to allow greater blood flow to the kidneys.

An example of renal denervation therapy being delivered. A catheter is inserted into the renal artery to ablate the nerves in the vessel wall that regulate vasoconstriction. This leaves the vessel permanently in the widest open position to allow greater blood flow to the kidneys.

Feature | Renal Denervation | May 30, 2018
May 30, 2018 — Despite the best efforts of clinicians to manage hypertension, it continues to increase and is now rea
Paradise Renal Denervation System Shows Significant Blood Pressure Reduction in Hypertensive Patients. PCR, #euroPCR 2018
News | Renal Denervation | May 30, 2018
ReCor Medical announced that the RADIANCE-HTN SOLO study met its primary efficacy endpoint and demonstrated a...
Renal Denervation Shows Significant Drop in Hypertension
News | Renal Denervation | May 23, 2018
At the 2018 EuroPCR Annual Meeting in Paris, Medtronic announced first-ever-data from the SPYRAL HTN-ON MED Study....
Medtronic Announces Renal Denervation Pivotal Trial for Hypertension Treatment
News | Renal Denervation | April 16, 2018
Medtronic plc announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (...
SPYRAL HTN-OFF MED Study Results Show Efficacy, Safety of Renal Denervation
News | Renal Denervation | August 31, 2017
Medtronic plc announced its intent to move forward with a new renal denervation pivotal trial following positive first...
News | Renal Denervation | October 11, 2016
Awards from the National Institutes of Health’s Common Fund are supporting research on the peripheral nervous system,...